Tag: racks
COVID-19 fighter remdesivir racks up $873M as Gilead plays defense on...
Gilead Sciences started charging for remdesivir in July. Given its status then as the only drug authorized for COVID-19 in the U.S., industry watchers...
ESC: Novartis’ Entresto racks up a heart failure study win—but it’s...
As the bestselling drug in the heart failure space, Novartis' Entresto suffered a stinging setback last year in a novel indication—but there were some...